Chinese Health (301408.SZ) subsidiary received a notice of acceptance of ferrous succinate tablet drug registration

Zhitong Finance App News, Chinese Health (301408.SZ) issued an announcement. Recently, Anhui Zhengyao Pharmaceutical Technology Co., Ltd., a wholly-owned subsidiary of the company, received the “Notice of Acceptance” of the application for registration and marketing of ferrous succinate tablets issued by the State Drug Administration.

Ferrous succinate tablets are anti-anemia drugs, mainly used to treat and prevent iron deficiency anemia. Oral administration of this product can supplement iron to correct iron deficiency anemia. It is suitable for treating iron deficiency anemia in adults and children due to chronic blood loss, insufficient iron intake, absorption disorder, etc., and is also suitable for preventing iron deficiency anemia in adults, pregnant women and children. Patients should use the treatment dosage according to the instructions for use of the drug after being diagnosed with iron deficiency anemia. When used for routine prophylactic iron supplementation, prophylactic doses should be used.